Coutte Laetitia, Dreyer Chantal, Sablin Marie-Paule, Faivre Sandrine, Raymond Eric
Hôpital Beaujon, service interhospitalier de cancérologie, 100, boulevard du Général-Leclerc, 92118 Clichy Cedex, France.
Bull Cancer. 2012 Feb 1;99(2):173-80. doi: 10.1684/bdc.2011.1384.
PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developed or being developed in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored.
PI3K/AKT/mTOR信号通路是一条由不同激酶组成的细胞内信号通路。该通路中存在许多蛋白质突变，这些突变导致细胞生长、增殖、存活和血管生成的失调。雷帕霉素是一种抑制mTOR的抗生素。在抗肿瘤治疗中，已开发或正在开发雷帕霉素的不同类似物，其中替西罗莫司、依维莫司和地佛莫司在肾癌和套细胞淋巴瘤中显示出抗肿瘤活性，并且在其他肿瘤中也有许多临床试验正在进行。未来，需要确定反应的预测因素；应探索患者选择以及与化疗或其他靶向治疗的联合使用。
